BCL2 and cancer: The antiangiogenic properties through inhibition of VEGFR and PDGFR in endothelial cells are thought to be the key to its efficacy, but sorafenib has also been shown to demonstrate apoptotic effects on cancer cell lines through regulation of MCL-1 and the BCL-2 family of proteins [33,34].